Zacks Investment Research downgraded Hercules Capital Inc (NYSE:HTGC) to Hold in a report released today.
- Updated: October 5, 2016
Zacks Investment Research has downgraded Hercules Capital Inc (NYSE:HTGC) to Hold in a report released on 10/5/2016.
Previously on 10/04/2016, Zacks Investment Research reported about Hercules Capital Inc (NYSE:HTGC) raised the target price from $0.00 to $15.00. At the time, this indicated a possible upside of 0.10%.
Yesterday Hercules Capital Inc (NYSE:HTGC) traded 0.59% higher at $13.60. The company’s 50-day moving average is $13.55 and its 200-day moving average is $12.70. The last stock close price is up 7.20% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 301,100 shares of the stock were exchanged, up from an average trading volume of 283,309
See Chart Below
Hercules Capital Inc has a 52 week low of $9.92 and a 52 week high of $14.00 with a P/E ratio of 24.17 The company’s market cap is currently $0.
In addition to Zacks Investment Research reporting its target price, a total of 10 brokers have issued a report on the stock. The consensus target price is $13.45 with 3 brokers rating the stock a strong buy, 6 brokers rating the stock a buy, 4 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
General Information About Hercules Capital Inc (NYSE:HTGC)
Hercules Capital, Inc., formerly Hercules Technology Growth Capital, Inc., is a specialty finance company. The Company is focused on providing senior secured venture growth loans to venture capital-backed companies in a range of technology, life sciences and sustainable and renewable technology industries. The Company is an internally managed, non-diversified, closed-end investment company. The Company focuses its investments in companies active in the technology industry sub-sectors characterized by products or services, including computer software and hardware; networking systems; semiconductors; semiconductor capital equipment; information technology infrastructure or services; Internet consumer and business services; telecommunications; telecommunications equipment, and media. Within the life science sub-sector, the Company focuses on medical devices, bio-pharmaceutical, drug discovery, drug delivery, healthcare services and information systems companies.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.